<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D3BD17EA-7310-43F3-A920-46864ED0A1B5"><gtr:id>D3BD17EA-7310-43F3-A920-46864ED0A1B5</gtr:id><gtr:name>Proteome Sciences plc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D3BD17EA-7310-43F3-A920-46864ED0A1B5"><gtr:id>D3BD17EA-7310-43F3-A920-46864ED0A1B5</gtr:id><gtr:name>Proteome Sciences plc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A977029A-3651-4B71-B462-BF4F58C278B9"><gtr:id>A977029A-3651-4B71-B462-BF4F58C278B9</gtr:id><gtr:firstName>Brian</gtr:firstName><gtr:surname>Anderton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8C2686BF-665F-4B6D-A835-FD1D1AA924D3"><gtr:id>8C2686BF-665F-4B6D-A835-FD1D1AA924D3</gtr:id><gtr:firstName>Michael Philip</gtr:firstName><gtr:surname>Coleman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1AD81458-D7F1-4E1D-9D49-DA319E1C5D6C"><gtr:id>1AD81458-D7F1-4E1D-9D49-DA319E1C5D6C</gtr:id><gtr:firstName>Diane</gtr:firstName><gtr:surname>Hanger</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/24A3D49E-2F60-4CE9-BBD5-5D6CDF8D7599"><gtr:id>24A3D49E-2F60-4CE9-BBD5-5D6CDF8D7599</gtr:id><gtr:firstName>Piers</gtr:firstName><gtr:surname>Emson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0300408"><gtr:id>33BBAED1-3730-4B3F-A5BD-710328BB7311</gtr:id><gtr:title>The mechanism and regulation of axonal transport of tau</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0300408</gtr:grantReference><gtr:abstractText>Alzheimer?s disease is the most common neurodegenerative disease, affecting over half a million elderly people in the UK and representing around 1% of the population. The present demographic change is set to continue and so there will be a rising proportion of affected people. Although there are now some effective treatments, these are all symptomatic and do not halt or slow the relentless loss of nerve cells in the brain, such that after a while the treatments fail and patients continue to deteriorate and die. In the case of Alzheimer?s disease, the nerve cells that die are those required for higher functions of the brain, including memory and cognition, whereas cells important for movement are relatively spared. Hence Alzheimer patients are perfectly able to walk, at least until the more advanced stages, but early on in the disease have memory difficulties. There are two characteristic abnormalities in the brain in Alzheimer?s disease: these are the presence of senile plaques and neurofibrillary tangles. The senile plaques have a central deposit of a protein known as amyloid and new drugs aimed at preventing amyloid production are being developed. Less is known about the neurofibrillary tangles, which are made of another protein called tau. However, it has been discovered recently that mutations in the gene for tau give rise to some other neurodegenerative diseases related to Alzheimer?s disease but that these other conditions have no amyloid deposits. This has led to the realisation that tau or neurofibrillary tangles are also important in Alzheimer?s disease and their presence inside nerve cells may well directly result in death of those cells. This project is aimed at understanding how tau becomes abnormal and forms the neurofibrillary tangles since it will then be possible to devise strategies to prevent tangle formation and hopefully prevent death of the nerve cells, which may be a much more effective treatment than we presently have available because it would tackle the underlying disease process. The successful outcome of the project will therefore help validate drug discovery programmes that are directed at enzymes known as protein kinases that modify tau and hence believed to be potentially useful targets; the project it may also lead to the discovery of new drug targets for treating Alzheimer?s disease.</gtr:abstractText><gtr:technicalSummary>Intraneuronal inclusions in Alzheimer?s disease and related tauopathies are composed of aggregated and hyperphosphorylated tau. Tau inclusions are generally believed to lead directly to neuronal cell dysfunction and death. So far, the mechanism by which the normal form of tau is transformed into filamentous aggregates and kills cells has eluded researchers. One hypothesis is that defective axonal transport resulting from hyperphosphorylation of tau is an important neurodegenerative mechanism, giving rise to a local increase in concentrations of tau, followed by its aggregation and disruption of transport of other organelles. We propose to address this hypothesis by investigating the mechanism and regulation of axonal transport of tau and determining if mutations and pathological phosphorylation of tau adversely affect its transport and that of other organelles. Our objectives are to model in transgenic mice the effects of introducing (knock-in) a known miss-sense mutation in tau and knock-in mimics of hyperphosphorylated tau on axonal transport of tau and organelles and the behavioural and pathological consequences of these mutant forms of tau. We shall treat cultured neurons expressing EGFP-tagged tau with pharmacological agents or siRNA to modulate protein phosphorylation in order to determine which protein kinases and phosphatases regulate physiological tau phosphorylation and which of these influence transport of tau and organelles in cultured neurons, as assessed by real-time video, differential interference and confocal microscopy. We shall use a quantitative mass spectrometry approach to identify phosphorylation sites for different protein kinases and phosphatases. We shall make additional tau phosphomimic transgenic mice and use the same neuronal culture system to model the effects of interfering with critical phosphorylation sites involved in the regulation of axonal transport of tau and organelles and determine the influence of phosphorylation at these sites on in vitro microtubule dynamics. We shall prepare monoclonal antibodies to any novel phosphorylation sites in tau to investigate the status of such sites in normal and pathological brain tissue. We shall use pull-down techniques to characterise the complement of proteins in the tau transport complex, including determining if this complex is affected by known disease-causing mutations in tau or by phosphorylation. We shall use pull-down techniques and mass spectrometry to determine the molecular mechanisms underlying tau axonal transport by identifying the molecular motors involved and how phosphorylation changes modulate tau transport. The outcome will be clearer picture of the role of phosphorylation in tau pathology and possibly the identification of novel drug targets.</gtr:technicalSummary><gtr:fund><gtr:end>2011-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1651043</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Proteome Sciences plc</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Proteome Sciences</gtr:description><gtr:id>DBAFCBCE-B9D6-480A-918B-28954D7FB7CE</gtr:id><gtr:impact>PMID: 17562708</gtr:impact><gtr:outcomeId>668282A8C81-1</gtr:outcomeId><gtr:partnerContribution>Mass spectrometry of phosphorylated proteins</gtr:partnerContribution><gtr:piContribution>Generation of material for mass spectrometric analysis</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>EC FP6 Collaborative Projects</gtr:department><gtr:description>FP6 network NeuronE</gtr:description><gtr:id>F429CE73-4F44-42F3-B7C7-CB442A0D760A</gtr:id><gtr:impact>Presentations at annual meetings, including results with P301L tau mouse</gtr:impact><gtr:outcomeId>atby1cjMSof-1</gtr:outcomeId><gtr:partnerContribution>Enhanced EU networking (MC)</gtr:partnerContribution><gtr:piContribution>Invited member of FP6 network NeuronE (MC)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Wikipedia</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7F7A04A1-3C8A-4279-9461-19BD0640B147</gtr:id><gtr:impact>Edited pages on axon degeneration in Wikipedia (MC)

Edited pages on axon degeneration in Wikipedia</gtr:impact><gtr:outcomeId>frZWHFRo8mZ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lay talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6E18A8DC-E08E-4207-9B20-711F35BF6708</gtr:id><gtr:impact>Lay talk at an ART fundraising lunch (MC)

Raising awareness</gtr:impact><gtr:outcomeId>rpE15pXRHXx</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit to Babraham Institute</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6A1DE1B3-0A60-491F-AA45-54C1D6012196</gtr:id><gtr:impact>Group discussions of research data and hands-on practical experience to school children

Interest in science</gtr:impact><gtr:outcomeId>noomRzaxon1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Year 12 mock interviews</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>24A99B3B-E317-4A88-A446-E2404D1D3015</gtr:id><gtr:impact>Year 12 school students underwent formal mock interviews

School reports that this is very useful for students preparing for university and for taking up employment after leaving school</gtr:impact><gtr:outcomeId>5432a587c1d581.84891574</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011,2012,2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>124346FD-4015-47D7-9A8D-3D3559633217</gtr:id><gtr:impact>Demonstrations at MRC Centre for Neurodegeneration Research Open Day

Not known</gtr:impact><gtr:outcomeId>CB406124F2E</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ARUK Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D83B79DC-3B57-4B6C-9491-2CCE7F0E8283</gtr:id><gtr:impact>120 members of the public attended an Open Day at the Institute of Psychiatry, Psychology &amp;amp; Neuroscience, King's College London

This event is always over-subscribed and has positive feedback from attendees</gtr:impact><gtr:outcomeId>538da1b655b708.21472966</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013,2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cambridge Science Festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8809632A-E609-4CCC-B46F-91C7317B2342</gtr:id><gtr:impact>Cambridge Science Festival demonstration from Babraham Institute (MC)

Cambridge Science Festival</gtr:impact><gtr:outcomeId>AX8U8cdrHYN</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Report</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E3030C47-DD35-456D-9A36-AD5833151CE1</gtr:id><gtr:impact>Article provided on work in my reseearch group which was published in the Institute of Psychiatry Annual Research Report

Not known</gtr:impact><gtr:outcomeId>05F35071E77</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8C1B87AF-98A2-4EC7-9B23-2F94998D70D3</gtr:id><gtr:impact>Presentations to members of the public at the MRC Centre for Neurodegeneration Open Day, King's College London

Presentation of information</gtr:impact><gtr:outcomeId>707D4A7DB39</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PSP Bulletin</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>19526070-96FB-4DC0-887B-F511E4D89469</gtr:id><gtr:impact>Regular contributions describing progress to the Progressive Supranuclear Palsy Association Bulletin

Not known</gtr:impact><gtr:outcomeId>A7967548589</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>896584</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC project grant</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>27CB72FB-D5A1-4D16-AC84-24F5C860B794</gtr:id><gtr:outcomeId>GKzJVgyURez0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>96000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BI project grant/Babraham Institute</gtr:description><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>C787DB55-0810-4118-8BEB-3628ED8244A0</gtr:id><gtr:outcomeId>PzL4u8iHATs0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>93227</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARUK PhD Scholarship</gtr:description><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>6BDFB649-4B3F-4244-9B8B-79D27E57F612</gtr:id><gtr:outcomeId>mRu8a9rNQi30</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>210000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HSC project grant</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>The Henry Smith Charity</gtr:fundingOrg><gtr:id>89AA4579-9833-480A-8145-E0F3A68E1134</gtr:id><gtr:outcomeId>B42644A61EA0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>63000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CHDI project</gtr:description><gtr:fundingOrg>CHDI Foundation</gtr:fundingOrg><gtr:id>FC4E32AE-EA1B-4A87-9069-443656DB43E1</gtr:id><gtr:outcomeId>fB6V5eEMmoP0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>220297</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARUK Travelling Research Fellowship</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>573E082F-1524-406F-9729-30279138956C</gtr:id><gtr:outcomeId>GqXL1TASnYT0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>284092</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ART project grant</gtr:description><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>4E8490E3-A495-42DF-AADA-24FFD679E1EB</gtr:id><gtr:outcomeId>m2sD1zAe9Sk0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>88720</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ART PhD Studentship</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>59C4488E-2E01-4519-BAA1-65ECD0BFA1F9</gtr:id><gtr:outcomeId>74E41647F200</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Tau phosphorylation sites identified on material extracted from human brain. Methods for screening for substances capable of modulating the phosphorylation of tau protein are disclosed, and in particular paired helical filament (PHF) tau, and the use of such modulators in the treatment of tauopathies. The assays and screening methods are based on the identification of new phosphorylation sites in PHF tau and new kinases and combinations of kinases as therapeutic targets, in particular the identification of casein kinase 1 as a kinase which phosphorylates tau protein.</gtr:description><gtr:grantRef>G0300408</gtr:grantRef><gtr:id>C6A87AB6-41A4-4A93-BC7F-3BDF44A4C72B</gtr:id><gtr:impact>PMID: 17562708</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>BF4C54D2D97</gtr:outcomeId><gtr:patentId>WO2005001114</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Tau phosphorylation sites</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>N/A</gtr:description><gtr:grantRef>G0300408</gtr:grantRef><gtr:id>3C142B25-64DB-4002-AAD6-E95CF61F4927</gtr:id><gtr:impact>Publications, as listed
PATENT APPLICATION TERMINATED 2010</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>hg7bjvxktnx</gtr:outcomeId><gtr:patentId>GB0902147.8</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Nmnat2 modulator</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Tau phosphorylation-mimic transgenic mice</gtr:description><gtr:id>98F0102F-9B91-4738-A233-307C43DD9C03</gtr:id><gtr:impact>These animals are currently being characterised</gtr:impact><gtr:outcomeId>RzujE9q2JiT</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Phosphorylation-mimic transgenic mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Tau phosphorylation-deficient transgenic mice</gtr:description><gtr:id>784FF8ED-32CB-4906-ADAE-DE37151AF364</gtr:id><gtr:impact>These animals are currently being characterised</gtr:impact><gtr:outcomeId>Namyuv7FgCL</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Phosphorylation-deficient transgenic mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Phospho-mimic and phospho-defective tau mutant cDNA constructs</gtr:description><gtr:id>B657EF67-453D-46E6-938C-EC24FAA499F6</gtr:id><gtr:impact>Used to generate transgenic mice. Also used in cellular systems to mimic effects of disease. Used in publications.</gtr:impact><gtr:outcomeId>rGovY6mptCF</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Tau mutant cDNA constructs</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Tau P301L knockin transgenic mice</gtr:description><gtr:id>C6BA5977-CB0F-4D0A-9930-26015F848FC1</gtr:id><gtr:impact>Manuscript on P301L mice accepted for publication
Material used to provide preliminary data for grant applications.</gtr:impact><gtr:outcomeId>D8E23B8D792</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>P301L tau transgenic mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>ImageJ plugins for fully automated analysis of multiple axonal transport parameters</gtr:description><gtr:id>11CD9AC7-DFC4-4A20-804D-06C3DF903B1D</gtr:id><gtr:impact>Access to new method through publically available ImageJ software.
Use in publication</gtr:impact><gtr:outcomeId>GJe29EjW6FC</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Axonal transport measurement</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Proteome Sciences plc</gtr:companyName><gtr:description>http://www.proteomics.com/</gtr:description><gtr:id>26E98CE7-F1B4-4125-9D2F-A30A58D2C9D2</gtr:id><gtr:impact>Joint patents with King's College London relating to tau phosphorylation in Alzheimer's disease.
Development of TMT methodology for quantitative proteomics.
Biomarker assays</gtr:impact><gtr:outcomeId>fG1zHTQnZMw</gtr:outcomeId><gtr:url>http://www.proteomics.com/products-and-services/cns/alzheimers-plasma-9-plex</gtr:url></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>32E1C972-0AE3-48A2-9B0A-BB402FA44037</gtr:id><gtr:title>Kinase activities increase during the development of tauopathy in htau mice.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33488ddeacacc670155f4970e13fadf6"><gtr:id>33488ddeacacc670155f4970e13fadf6</gtr:id><gtr:otherNames>Kelleher I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>CBC3BAA6EB0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D166E1F-49DA-422B-95D7-AE6C665EFD3B</gtr:id><gtr:title>Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0e4ecbab5f8ec94e21af637cfb1c561"><gtr:id>a0e4ecbab5f8ec94e21af637cfb1c561</gtr:id><gtr:otherNames>Cuchillo-Ibanez I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>796035E8EDF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76010E9F-546D-44A5-83E3-F63B7C174F12</gtr:id><gtr:title>Targeting NMNAT1 to axons and synapses transforms its neuroprotective potency in vivo.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23a120194479d20b002d1f5f1bbc9b03"><gtr:id>23a120194479d20b002d1f5f1bbc9b03</gtr:id><gtr:otherNames>Babetto E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>CjXxeTKNvB7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>921DDD40-A647-4A42-BBF3-1137B63BA08F</gtr:id><gtr:title>A role for tau at the synapse in Alzheimer's disease pathogenesis.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/575e0a2595915220a4a67582c7d62d97"><gtr:id>575e0a2595915220a4a67582c7d62d97</gtr:id><gtr:otherNames>Pooler AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>pm_13628_28_24076336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62C0095A-2400-4F65-B84A-11F8F897F642</gtr:id><gtr:title>Abeta, tau and ApoE4 in Alzheimer's disease: the axonal connection.</gtr:title><gtr:parentPublicationTitle>Trends in molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e8e5a977709d524d14a969a1a1ce957"><gtr:id>5e8e5a977709d524d14a969a1a1ce957</gtr:id><gtr:otherNames>Adalbert R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1471-4914</gtr:issn><gtr:outcomeId>Bho3ECjhUQD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1CBB2D4-9DE9-4580-A674-6BD6FB7961ED</gtr:id><gtr:title>Functional implications of the association of tau with the plasma membrane.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/575e0a2595915220a4a67582c7d62d97"><gtr:id>575e0a2595915220a4a67582c7d62d97</gtr:id><gtr:otherNames>Pooler AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>UhEkw1PtvsR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>503EE169-1702-470F-8CAD-0454E7F759F3</gtr:id><gtr:title>The importance of tau phosphorylation for neurodegenerative diseases.</gtr:title><gtr:parentPublicationTitle>Frontiers in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6181eaa28be814c0816a3195a16c5e23"><gtr:id>6181eaa28be814c0816a3195a16c5e23</gtr:id><gtr:otherNames>Noble W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1664-2295</gtr:issn><gtr:outcomeId>pm_13628_28_23847585</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDBD22CD-02D8-4C7D-8816-5427949782F3</gtr:id><gtr:title>Tau phosphorylation affects its axonal transport and degradation.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34ccfb591443e7db7227530de21d9b2a"><gtr:id>34ccfb591443e7db7227530de21d9b2a</gtr:id><gtr:otherNames>Rodr?guez-Mart?n T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_13628_28_23601672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12047C11-F677-4635-BF1F-8C6F1577E6F7</gtr:id><gtr:title>Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e775577e058c629edaa52170e133fdc"><gtr:id>6e775577e058c629edaa52170e133fdc</gtr:id><gtr:otherNames>Gilley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn><gtr:outcomeId>A9D520FF2E5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1E93B0A-E3E1-43D8-954A-54F78D68B4E4</gtr:id><gtr:title>Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.</gtr:title><gtr:parentPublicationTitle>Trends in molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03fdb5d2f4810671899a9cfd187a984a"><gtr:id>03fdb5d2f4810671899a9cfd187a984a</gtr:id><gtr:otherNames>Hanger DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1471-4914</gtr:issn><gtr:outcomeId>F528C9B533E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EDED268-91B7-4A1B-9754-F2E3B8C490B8</gtr:id><gtr:title>The microtubule-associated protein tau is phosphorylated by Syk.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/052148e8fe0c44cfc5b23cde4a239956"><gtr:id>052148e8fe0c44cfc5b23cde4a239956</gtr:id><gtr:otherNames>Lebouvier T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>88388CB749A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83234C41-FAC8-478B-820E-1E900809B61B</gtr:id><gtr:title>Non-nuclear Wld(S) determines its neuroprotective efficacy for axons and synapses in vivo.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e2ad544a2dcdfe5b95ceb680fc2b4da"><gtr:id>1e2ad544a2dcdfe5b95ceb680fc2b4da</gtr:id><gtr:otherNames>Beirowski B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>pQ7iWDP8cCY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47CF7F9A-B4C8-4E74-A58E-34802B979C54</gtr:id><gtr:title>Wld S protein requires Nmnat activity and a short N-terminal sequence to protect axons in mice.</gtr:title><gtr:parentPublicationTitle>The Journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48c8fdc8b340458d25f8cd9c1f056b93"><gtr:id>48c8fdc8b340458d25f8cd9c1f056b93</gtr:id><gtr:otherNames>Conforti L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9525</gtr:issn><gtr:outcomeId>BqBvV7yaMAX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A6056B8-5F41-499E-AEBB-911AFAD50F59</gtr:id><gtr:title>Modification of the Drosophila model of in vivo Tau toxicity reveals protective phosphorylation by GSK3?.</gtr:title><gtr:parentPublicationTitle>Biology open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5d77c07b64733f80e472fde39168e91"><gtr:id>b5d77c07b64733f80e472fde39168e91</gtr:id><gtr:otherNames>Povellato G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2046-6390</gtr:issn><gtr:outcomeId>doi_55f983983703f17d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCA92E9C-9040-45B4-8485-121F5278C3E1</gtr:id><gtr:title>Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03fdb5d2f4810671899a9cfd187a984a"><gtr:id>03fdb5d2f4810671899a9cfd187a984a</gtr:id><gtr:otherNames>Hanger DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>0B1E7419172</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38C02AD0-8C0C-4CD4-8626-28280D9AFD03</gtr:id><gtr:title>Tau cleavage and tau aggregation in neurodegenerative disease.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03fdb5d2f4810671899a9cfd187a984a"><gtr:id>03fdb5d2f4810671899a9cfd187a984a</gtr:id><gtr:otherNames>Hanger DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>Wce6uDnDnaS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08E6D331-314E-44D4-87AB-016786E7D9F2</gtr:id><gtr:title>The microtubule-associated protein tau is also phosphorylated on tyrosine.</gtr:title><gtr:parentPublicationTitle>Journal of Alzheimer's disease : JAD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/052148e8fe0c44cfc5b23cde4a239956"><gtr:id>052148e8fe0c44cfc5b23cde4a239956</gtr:id><gtr:otherNames>Lebouvier T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1387-2877</gtr:issn><gtr:outcomeId>468B114E6BB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E01A4AF1-2B72-44B3-9CA6-9E33E6723D32</gtr:id><gtr:title>Difference Tracker: ImageJ plugins for fully automated analysis of multiple axonal transport parameters.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24ad3fe2e0292b6202ffad7a7b84a060"><gtr:id>24ad3fe2e0292b6202ffad7a7b84a060</gtr:id><gtr:otherNames>Andrews S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0165-0270</gtr:issn><gtr:outcomeId>EpVm2NDeg5v</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4207A60-38DD-4BDD-8309-D26E7910D176</gtr:id><gtr:title>Transgenic mouse models of tauopathy in drug discovery.</gtr:title><gtr:parentPublicationTitle>CNS &amp; neurological disorders drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6181eaa28be814c0816a3195a16c5e23"><gtr:id>6181eaa28be814c0816a3195a16c5e23</gtr:id><gtr:otherNames>Noble W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1871-5273</gtr:issn><gtr:outcomeId>nYUgmGYHWq3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF9B1BAD-26BB-4DD6-9CD8-50DC2770027E</gtr:id><gtr:title>Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a &amp;quot;P301L&amp;quot; tau knockin mouse.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e775577e058c629edaa52170e133fdc"><gtr:id>6e775577e058c629edaa52170e133fdc</gtr:id><gtr:otherNames>Gilley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>owTe8QkPdj8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB4FDE4F-DF52-4EC1-B261-86E08DD4A2DF</gtr:id><gtr:title>Reduced number of axonal mitochondria and tau hypophosphorylation in mouse P301L tau knockin neurons.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34ccfb591443e7db7227530de21d9b2a"><gtr:id>34ccfb591443e7db7227530de21d9b2a</gtr:id><gtr:otherNames>Rodr?guez-Mart?n T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>5720845455eff9.17406473</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>084E6A5E-DD7E-46AA-9D22-C5D29991FD9F</gtr:id><gtr:title>Mislocalization of neuronal tau in the absence of tangle pathology in phosphomutant tau knockin mice.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e775577e058c629edaa52170e133fdc"><gtr:id>6e775577e058c629edaa52170e133fdc</gtr:id><gtr:otherNames>Gilley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56d94ab63e5f88.55826075</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3E6B5E1-4BE9-4C8A-9593-473DCF2EC0B3</gtr:id><gtr:title>Mediators of tau phosphorylation in the pathogenesis of Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Expert review of neurotherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03fdb5d2f4810671899a9cfd187a984a"><gtr:id>03fdb5d2f4810671899a9cfd187a984a</gtr:id><gtr:otherNames>Hanger DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1473-7175</gtr:issn><gtr:outcomeId>213154E3A56</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>184E762E-DAE3-43AC-9D82-B07E1EFEFF7C</gtr:id><gtr:title>Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6f2832fa116198319dd3fcbf30106fd"><gtr:id>a6f2832fa116198319dd3fcbf30106fd</gtr:id><gtr:otherNames>Reynolds CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>165C9D8A521</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0300408</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>